表紙
市場調查報告書

進行性肌肉骨化症(進行性骨化性肌炎):開發中產品分析

Fibrodysplasia Ossificans Progressiva (Myositis Ossificans Progressiva) - Pipeline Review, H2 2019

出版商 Global Markets Direct 商品編碼 410990
出版日期 內容資訊 英文 78 Pages
訂單完成後即時交付
價格
Back to Top
進行性肌肉骨化症(進行性骨化性肌炎):開發中產品分析 Fibrodysplasia Ossificans Progressiva (Myositis Ossificans Progressiva) - Pipeline Review, H2 2019
出版日期: 2019年12月16日內容資訊: 英文 78 Pages
簡介

進行性肌肉骨化症 (FOP) ,是肌肉組織及肌腱、韌帶的結締組織慢慢被骨替代(骨化)的疾病。症狀有纖維組織腫脹、疼痛、發熱、肌肉的骨化,關節動作的限制等。透過手術及藥物治療,緩和疼痛和發炎等症狀。

本報告提供進行性肌肉骨化症(進行性骨化性肌炎)的治療藥開發平台的現狀及最新更新的各開發階段比較分析,企業和研究機關最新的新聞和發表開發中的治療藥,治療藥的評估,後期階段及中止的計劃相關資訊等。

簡介

  • 調查範圍

進行性肌肉骨化症(進行性骨化性肌炎)概要

治療藥的開發

  • 開發中產品;概要

企業開發中的治療藥

開發中產品概況

  • 臨床實驗階段的產品
  • 初期階段的產品

企業開發中的產品

開發治療藥的企業

  • Clementia Pharmaceuticals Inc
  • 第一三共
  • Heart Metabolics Ltd
  • La Jolla Pharmaceutical Company
  • Oncodesign SA
  • Pfizer Inc
  • Regeneron Pharmaceuticals Inc

治療藥的評估

  • 單劑產品
  • 各標的
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

產品開發里程碑

  • 主要消息和新聞稿

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC11692IDB

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Fibrodysplasia Ossificans Progressiva - Pipeline Review, H2 2019, provides an overview of the Fibrodysplasia Ossificans Progressiva (Musculoskeletal Disorders) pipeline landscape.

Fibrodysplasia ossificans progressiva (FOP) is a disorder in which muscle tissue and connective tissue such as tendons and ligaments are gradually replaced by bone (ossified), forming bone outside that constrains movement. Symptoms swellings in fibrous tissue, pain, fever, muscle ossification and restricted movement of joints. Treatment includes surgery and medications to help relieve symptoms of FOP, such as pain and inflammation.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Fibrodysplasia Ossificans Progressiva - Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for Fibrodysplasia Ossificans Progressiva (Musculoskeletal Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Fibrodysplasia Ossificans Progressiva (Musculoskeletal Disorders) pipeline guide also reviews of key players involved in therapeutic development for Fibrodysplasia Ossificans Progressiva (Myositis Ossificans Progressiva) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 2, 4, 5 and 1 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 2 and 1 molecules, respectively.

Fibrodysplasia Ossificans Progressiva (Musculoskeletal Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Fibrodysplasia Ossificans Progressiva (Musculoskeletal Disorders).
  • The pipeline guide reviews pipeline therapeutics for Fibrodysplasia Ossificans Progressiva (Musculoskeletal Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Fibrodysplasia Ossificans Progressiva (Musculoskeletal Disorders) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Fibrodysplasia Ossificans Progressiva (Musculoskeletal Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Fibrodysplasia Ossificans Progressiva (Musculoskeletal Disorders)

Reasons to buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Fibrodysplasia Ossificans Progressiva (Musculoskeletal Disorders).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Fibrodysplasia Ossificans Progressiva (Musculoskeletal Disorders) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • List of Tables
  • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Fibrodysplasia Ossificans Progressiva (Myositis Ossificans Progressiva) - Overview
  • Fibrodysplasia Ossificans Progressiva (Myositis Ossificans Progressiva) - Therapeutics Development
    • Pipeline Overview
    • Pipeline by Companies
    • Pipeline by Universities/Institutes
    • Products under Development by Companies
    • Products under Development by Universities/Institutes
  • Fibrodysplasia Ossificans Progressiva (Myositis Ossificans Progressiva) - Therapeutics Assessment
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Fibrodysplasia Ossificans Progressiva (Myositis Ossificans Progressiva) - Companies Involved in Therapeutics Development
    • AstraZeneca Plc
    • BioCryst Pharmaceuticals Inc
    • Clementia Pharmaceuticals Inc
    • Daiichi Sankyo Co Ltd
    • Ipsen SA
    • Keros Therapeutics Inc
    • La Jolla Pharmaceutical Company
    • Oncodesign SA
    • Pfizer Inc
    • Regeneron Pharmaceuticals Inc
  • Fibrodysplasia Ossificans Progressiva (Myositis Ossificans Progressiva) - Drug Profiles
    • Antibody to Antagonize ALK2 for Fibrodysplasia Ossificans Progressiva - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • BCX-9250 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • BCX-9499 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • BLU-782 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • dipyridamole - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Drug for Fibrodysplasia Ossificans Progressiva - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • garetosmab - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • KER-047 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • palovarotene - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • saracatinib difumarate - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • sirolimus - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule 1 To Inhibit ALK2 for Fibrodysplasia Ossificans Progressiva - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule 2 To Inhibit ALK2 for Fibrodysplasia Ossificans Progressiva - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule to Inhibit Activin Receptor-Like Kinase 2 for fibrodysplasia ossificans progressiva - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule to Inhibit ALK2 for Fibrodysplasia Ossificans Progressiva - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • trevogrumab - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Fibrodysplasia Ossificans Progressiva (Myositis Ossificans Progressiva) - Dormant Projects
  • Fibrodysplasia Ossificans Progressiva (Myositis Ossificans Progressiva) - Product Development Milestones
    • Featured News & Press Releases
      • Dec 09, 2019: Ipsen initiates partial clinical hold for palovarotene IND120181 and IND135403 studies
      • Nov 04, 2019: BioCryst launches trial to treat fibrodysplasia ossificans progressiva
      • Oct 24, 2019: Oncodesign: publication of an article presenting promising results for the treatment of stone man syndrome (FOP)
      • Mar 27, 2019: Blueprint Medicines provides update on clinical progress of BLU-782
      • Feb 11, 2019: Clementia granted Rare Pediatric Disease Designation by FDA for Palovarotene for Fibrodysplasia Ossificans Progressiva
      • Oct 23, 2018: Clementia announces plan to submit a new drug application for Palovarotene for the treatment of FOP based on positive phase 2 results
      • Oct 02, 2018: Clementia initiates phase 1 clinical trial of palovarotene eye drop formulation in healthy volunteers
      • Oct 01, 2018: Blueprint Medicines presents foundational preclinical data supporting the development of BLU-782, a highly selective ALK2 Inhibitor, for the treatment of patients with fibrodysplasia ossificans progressiva
      • Sep 26, 2018: Clementia announces updated phase 2 part B data on Palovarotene for FOP
      • Sep 24, 2018: Blueprint Medicines to present data on BLU-782 at 2018 ASBMR annual meeting
      • Sep 05, 2018: Clementia to Present at ASBMR 2018 and Upcoming Investor Conferences
      • Aug 17, 2018: Clementia completes patient enrolment in phase 3 of MOVE Trial
      • May 23, 2018: Clementia Reports Positive Phase 2 Part B Data Showing Treatment with Palovarotene Significantly Reduces New Bone Growth in Patients with FOP
      • Jan 05, 2018: BioCryst Advancing Potential Treatment for Rare and Severely Debilitating Fibrodysplasia Ossificans Progressiva
      • Jan 05, 2018: BioCryst Provides Update on Drug Candidate BCX9499
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Fibrodysplasia Ossificans Progressiva (Myositis Ossificans Progressiva), H2 2019
  • Number of Products under Development by Companies, H2 2019
  • Number of Products under Development by Universities/Institutes, H2 2019
  • Products under Development by Companies, H2 2019
  • Products under Development by Universities/Institutes, H2 2019
  • Number of Products by Stage and Target, H2 2019
  • Number of Products by Stage and Mechanism of Action, H2 2019
  • Number of Products by Stage and Route of Administration, H2 2019
  • Number of Products by Stage and Molecule Type, H2 2019
  • Fibrodysplasia Ossificans Progressiva (Myositis Ossificans Progressiva) - Pipeline by AstraZeneca Plc, H2 2019
  • Fibrodysplasia Ossificans Progressiva (Myositis Ossificans Progressiva) - Pipeline by BioCryst Pharmaceuticals Inc, H2 2019
  • Fibrodysplasia Ossificans Progressiva (Myositis Ossificans Progressiva) - Pipeline by Clementia Pharmaceuticals Inc, H2 2019
  • Fibrodysplasia Ossificans Progressiva (Myositis Ossificans Progressiva) - Pipeline by Daiichi Sankyo Co Ltd, H2 2019
  • Fibrodysplasia Ossificans Progressiva (Myositis Ossificans Progressiva) - Pipeline by Ipsen SA, H2 2019
  • Fibrodysplasia Ossificans Progressiva (Myositis Ossificans Progressiva) - Pipeline by Keros Therapeutics Inc, H2 2019
  • Fibrodysplasia Ossificans Progressiva (Myositis Ossificans Progressiva) - Pipeline by La Jolla Pharmaceutical Company, H2 2019
  • Fibrodysplasia Ossificans Progressiva (Myositis Ossificans Progressiva) - Pipeline by Oncodesign SA, H2 2019
  • Fibrodysplasia Ossificans Progressiva (Myositis Ossificans Progressiva) - Pipeline by Pfizer Inc, H2 2019
  • Fibrodysplasia Ossificans Progressiva (Myositis Ossificans Progressiva) - Pipeline by Regeneron Pharmaceuticals Inc, H2 2019
  • Fibrodysplasia Ossificans Progressiva (Myositis Ossificans Progressiva) - Dormant Projects, H2 2019

List of Figures

  • Number of Products under Development for Fibrodysplasia Ossificans Progressiva (Myositis Ossificans Progressiva), H2 2019
  • Number of Products under Development by Companies, H2 2019
  • Number of Products under Development by Universities/Institutes, H2 2019
  • Number of Products by Targets, H2 2019
  • Number of Products by Stage and Targets, H2 2019
  • Number of Products by Mechanism of Actions, H2 2019
  • Number of Products by Stage and Mechanism of Actions, H2 2019
  • Number of Products by Routes of Administration, H2 2019
  • Number of Products by Stage and Routes of Administration, H2 2019
  • Number of Products by Molecule Types, H2 2019
  • Number of Products by Stage and Molecule Types, H2 2019
Back to Top